论文部分内容阅读
目的观察培美曲塞联合顺铂治疗老年晚期肺腺癌患者的治疗效果与安全性。方法 64例老年晚期肺腺癌患者,随机分成研究组与对照组,各32例。对照组行多西他赛联合顺铂静脉注入治疗,研究组行培美曲塞联合顺铂静脉注入治疗。观察两组疗效。结果两组疾病控制率(DCR)对比差异无统计学意义(P>0.05);研究组血液学毒性、白细胞下降以及消化道反应发生率均低于对照组(P<0.05)。结论治疗老年晚期肺腺癌患者应用培美曲塞联合顺铂,可提高治疗安全性。
Objective To observe the efficacy and safety of pemetrexed combined with cisplatin in the treatment of elderly patients with advanced lung adenocarcinoma. Methods 64 elderly patients with advanced lung adenocarcinoma were randomly divided into study group and control group, with 32 cases in each group. The control group received docetaxel plus cisplatin intravenously, and the study group received pemetrexed plus cisplatin intravenously. The two groups were observed. Results There was no significant difference in disease control rate (DCR) between the two groups (P> 0.05). The hematological toxicity, the leukopenia and the incidence of gastrointestinal reaction in the study group were lower than those in the control group (P <0.05). Conclusion Treatment of elderly patients with advanced lung adenocarcinoma with pemetrexed combined with cisplatin, can improve the safety of treatment.